Pharmacogenetics of Nicotine Addiction: Role of Dopamine

Overview

Journal Pharmacogenomics

Specialties Genetics
Pharmacology

Date 2014 Jan 22

PMID 24444411

Citations 26

Authors

Aryeh I Herman

Elise E DeVito

Kevin P Jensen

Mehmet Sofuoglu

Affiliations

Soon will be listed here.

Abstract

The neurotransmitter dopamine (DA) plays a central role in addictive disorders, including nicotine addiction. Specific DA-related gene variants have been studied to identify responsiveness to treatment for nicotine addiction. Genetic variants in DRD2, DRD4, ANKK1, DAT1, COMT and DBH genes show some promise in informing personalized prescribing of smoking cessation pharmacotherapies. However, many trials studying these variants had small samples, used retrospective design or were composed of mainly self-identified Caucasian individuals. Furthermore, many of these studies lacked a comprehensive measurement of nicotine metabolism rate, did not assess the roles of sex or the menstrual cycle, and did not investigate the role of rare variants and/or epigenetic factors. Future work should be conducted addressing these limitations to more effectively utilize DA genetic information to unlock the potential of smoking cessation pharmacogenetics.

Citing Articles

Exploring the therapeutic potential of tDCS, TMS and DBS in overcoming tobacco use disorder: an umbrella review.

Orru G, Baroni M, Conversano C, Gemignani A AIMS Neurosci. 2025; 11(4):449-467.

PMID: 39801797 PMC: 11712234. DOI: 10.3934/Neuroscience.2024027.

The association of genetic polymorphisms within the dopaminergic system with nicotine dependence: A narrative review.

Yang J, Wang H, Chen H, Hou H, Hu Q Heliyon. 2024; 10(12):e33158.

PMID: 39021905 PMC: 11253068. DOI: 10.1016/j.heliyon.2024.e33158.

Ameliorating effects of Acanthopanax koreanum extract and components on nicotine dependence and withdrawal symptoms.

Lee H, Ortiz D, Sayson L, Kim M, Cheong J, Kim H Addict Biol. 2024; 29(2):e13360.

PMID: 38380695 PMC: 10898842. DOI: 10.1111/adb.13360.

Structure-activity relationships andz interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm.

Thabet R, Alshar B, Alabdallah D, Alhmoud N, Alslameen S, Thabet Y J Int Med Res. 2023; 51(11):3000605231214065.

PMID: 38019107 PMC: 10687969. DOI: 10.1177/03000605231214065.

Pulmonary emphysema subtypes defined by unsupervised machine learning on CT scans.

Angelini E, Yang J, Balte P, Hoffman E, Manichaikul A, Sun Y Thorax. 2023; 78(11):1067-1079.

PMID: 37268414 PMC: 10592007. DOI: 10.1136/thorax-2022-219158.

References

Godtfredsen N, Holst C, Prescott E, Vestbo J, Osler M . Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol. 2002; 156(11):994-1001. DOI: 10.1093/aje/kwf150. View

Schnoll R, Johnson T, Lerman C . Genetics and smoking behavior. Curr Psychiatry Rep. 2007; 9(5):349-57. DOI: 10.1007/s11920-007-0045-3. View

Dempsey D, Tutka P, Jacob 3rd P, Allen F, Schoedel K, Tyndale R . Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004; 76(1):64-72. DOI: 10.1016/j.clpt.2004.02.011. View

Hirvonen M, Laakso A, Nagren K, Rinne J, Pohjalainen T, Hietala J . C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry. 2004; 9(12):1060-1. DOI: 10.1038/sj.mp.4001561. View

Benowitz N, Pomerleau O, Pomerleau C, Jacob 3rd P . Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res. 2003; 5(5):621-4. DOI: 10.1080/1462220031000158717. View

McGowan P, Sasaki A, DAlessio A, Dymov S, Labonte B, Szyf M . Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009; 12(3):342-8. PMC: 2944040. DOI: 10.1038/nn.2270. View

Li M, Cheng R, Ma J, Swan G . A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction. 2002; 98(1):23-31. DOI: 10.1046/j.1360-0443.2003.00295.x. View

Sofuoglu M, Herman A, Nadim H, Jatlow P . Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. Neuropsychopharmacology. 2012; 37(6):1509-16. PMC: 3327855. DOI: 10.1038/npp.2011.336. View

Hadjiconstantinou M, Neff N . Nicotine and endogenous opioids: neurochemical and pharmacological evidence. Neuropharmacology. 2010; 60(7-8):1209-20. DOI: 10.1016/j.neuropharm.2010.11.010. View

10.

Harrison P, Tunbridge E . Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology. 2007; 33(13):3037-45. DOI: 10.1038/sj.npp.1301543. View

11.

OGara C, Stapleton J, Sutherland G, Guindalini C, Neale B, Breen G . Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Genomics. 2007; 17(1):61-7. DOI: 10.1097/01.fpc.0000236328.18928.4c. View

12.

Lerman C, Shields P, Wileyto E, Audrain J, Hawk Jr L, Pinto A . Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 2003; 22(5):541-8. DOI: 10.1037/0278-6133.22.5.541. View

13.

Gozen O, Balkan B, Yildirim E, Koylu E, Pogun S . The epigenetic effect of nicotine on dopamine D1 receptor expression in rat prefrontal cortex. Synapse. 2013; 67(9):545-52. DOI: 10.1002/syn.21659. View

14.

Cobos A, Sanchez P, Aguado J, Carrasco J . Methodological quality in pharmacogenetic studies with binary assessment of treatment response: a review. Pharmacogenet Genomics. 2011; 21(5):243-50. DOI: 10.1097/FPC.0b013e32834300fb. View

15.

David S, Brown R, Papandonatos G, Kahler C, Lloyd-Richardson E, Munafo M . Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007; 9(8):821-33. PMC: 2039873. DOI: 10.1080/14622200701382033. View

16.

Urban T . Race, ethnicity, ancestry, and pharmacogenetics. Mt Sinai J Med. 2010; 77(2):133-9. DOI: 10.1002/msj.20168. View

17.

Perkins K, Scott J . Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res. 2008; 10(7):1245-50. DOI: 10.1080/14622200802097506. View

18.

Cinciripini P, Wetter D, Tomlinson G, Tsoh J, de Moor C, Cinciripini L . The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res. 2004; 6(2):229-39. DOI: 10.1080/14622200410001676396. View

19.

Middleton L, Apparsundaram S, King-Pospisil K, Dwoskin L . Nicotine increases dopamine transporter function in rat striatum through a trafficking-independent mechanism. Eur J Pharmacol. 2006; 554(2-3):128-36. PMC: 1920186. DOI: 10.1016/j.ejphar.2006.09.074. View

20.

David S, Johnstone E, Murphy M, Aveyard P, Guo B, Lerman C . Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug Alcohol Depend. 2008; 98(1-2):77-85. PMC: 4439462. DOI: 10.1016/j.drugalcdep.2008.04.013. View